KZR - NASDAQ
Kezar Life Sciences, Inc.
$7.29
+0.0000%Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
At a Glance
Live SnapshotKezar Life Sciences, Inc. Management Team
Zung To
Chief Development Officer
Marc L. Belsky
Chief Financial Officer & Secretary
Compensation
$653,208
Mark Schiller
Chief Operations Officer
Compensation
$637,985
Jack Taunton
Co-Founder
John Franklin Fowler
Co-Founder & Director
Compensation
$57,037
Christopher J. Kirk
Co-Founder, Chief Executive Officer & Director
Compensation
$927,300
Rachel Peterson
Head of Clinical Immunology
Pattie Chiang
Principal Accounting Officer, Senior Vice President & Corporate Controller
Neel K. Anand
Senior Vice President of Research & Drug Discovery
Joe Tedrick
Vice President of Human Resources
Kezar Life Sciences, Inc. Insider Positioning
During the last 12 months, insiders have sold $4K worth of KZR shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
825
3.53K
-4K
-$4K
Top Buyers
No buying activity
Top Sellers
Schiller Mark C.
Officer: Chief Operating Officer
$2K
Chiang Pichi Luo
Officer: Svp, Corporate Controller
$1K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $4K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
KZR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | April 26, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 14, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 26, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 25, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 24, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 25, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.